✦ LIBER ✦

PMH9 A PROBABILISTIC COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM, GENERIC CITALOPRAM AND VENLAFAXINE AS A FIRST-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN THE UNITED KINGDOM

✍ Scribed by ME Hemels; I Toumi; AG Wade

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A cost-effectiveness model of escitalopr

✍ Koen Demyttenaere; Michiel E.H. Hemels; Joumana Hudry; Lieven Annemans 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 860 KB

PMH11 PROBABILISTIC COST-EFFECTIVENESS A

✍ ME Hemels; I Toumi; AG Wade 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

PMH28 A COST-EFFECTIVENESS ANALYSIS OF E

✍ EP Armstrong; GH Skrepnek; DC Malone; H Erder 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

Cost-Effectiveness Evaluation in Sweden

✍ Göran Nordström; Natalya Danchenko; Nicolas Despiegel; Florence Marteau 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 810 KB

PMH60 A PHARMACOECONOMIC COMPARISON OF E

✍ AG Wade; JL Fernandez; C François; K Hansen; N Despiegel; N Danchenko 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

PMH25 An Assessement of the Cost-Effecti

✍ S. Druais; A. Gauthier; K. Demyttenaere; M. Brignone; A. De Pauw; G. Defraigne; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB